The latest news, announcements and press releases from Dendreon.
Filing for bankruptcy in 2014 might have seemed the end for Dendreon. But seven years later—and three rounds of being bought and sold—the company has resurfaced.
This week, Dendreon revealed plans to establish a CMO division offering end-to-end manufacturing of complex cell therapies. The company’s fortunes rose quickly with a once-thought to be promising prostate cancer drug, Provenge, but fell just as quickly because of the prohibitive cost of producing the cell therapy.
This is the News section of the company profile page for Dendreon on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
